- * Subjects who have completed the 2-year treatment and observation period in the Phase 3/4 Zemaira® CE1226_4001 study (NCT00261833) and are willing to sign informed consent
- * Males, and non-pregnant, non-lactating females, whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator
Influenza, Human
Flucelvax (TIVc or QIVc) Pregnancy Registry
NCT03438487 | PHASE 4 | OBSERVATIONAL
The study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with the TIVc or QIVc vaccine during pregnancy.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Syneos Health
Wilmington,North Carolina,United States,28405
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov